1. Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria;
2. Southwest Oncology Group, International Myeloma Foundation and Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA;
3. Roswell Park Cancer Institute, Buffalo, NY;
4. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Universitaria S. Giovanni Battista, Torino, Italy;
5. University Hospital of Salamanca, Salamanca, Spain;
6. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;
7. Haemato-Oncology Unit, Royal Marsden Hospital, London, United Kingdom;
8. Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;
9. Clinical Haematology/Bone Marrow Transplant Department, Alfred Hospital, Melbourne, Victoria, Australia;
10. Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;
11. Department of Hematology, Hospital Claude Huriez, Lille, France;
12. Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;
13. Department of Internal Medicine II, University Hospital, Würzburg, Germany;
14. Haga Hospital, The Hague, The Netherlands;
15. Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway;
16. Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;
17. Hematology Department, University Hospital, Nancy, France;
18. Weill Cornell Medical College, New York, NY;
19. University Medical Center, Utrecht, The Netherlands;
20. Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;
21. Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX;
22. WISP Research Institute, Langenfeld, Germany;
23. Seràgnoli Institute of Haematology, Bologna School of Medicine, S. Orsola's University Hospital, Bologna, Italy; and
24. Service d'Hématologie, Hospital Purpan, Toulouse, France